Latigo Bio shares positive news, appoints chief medical officer
Thousand Oaks-based Latigo Biotherapeutics, a company with the mission of creating non-opioid pain medication, shared positive phase 1 results for its lead candidate.
In its phase 1 clinical trial, data from LTG-001 showed that the oral treatment aimed to treat acute and chronic pain at its source was “well tolerated with rapid absorption.”
The trial had 72 healthy subjects and a Tmax of about 1.5 hours. Tmax refers to the time it takes for a drug to reach its maximum concentration in the body after administration.
Rapid onset of pain relief is critical for both acute and chronic pain management and achieving a Tmax in under two hours in this study indicates this may be possible, the press release said.
Additionally, no food effect was shown in the studied doses, the press release added.
“Opioid addiction is a national public health concern and Latigo Bio is dedicated to being part of the solution. Latigo intends to develop non-opioid drugs that have meaningful efficacy, rapid onset of action, and superior safety to standard of care with no central nervous system effects, thereby reducing the risk of addiction,” Nima Farzan, Latigo’s CEO, said in a press release.
“These positive Phase 1 results of LTG-001 in healthy volunteers are encouraging and give us tremendous confidence we are moving in the right direction.
Also, on Aug. 19, Latigo appointed Neil Singla as its chief medical officer.
Singla is the founder and past chief executive officer of Lotus Clinical Research, a world-renowned analgesic site and Clinical Research Organization combination.
According to the company, Singla has been instrumental in pioneering methodologies that enhance the rigor and outcomes of pain management studies.
“Latigo’s innovative approach to pain management can play a significant role in providing effective non-opioid therapies to patients,” Singla said in a press release.
“Latigo’s mission aligns with my passion for advancing treatments for pain management, without the risk of dependency. I am honored to have the opportunity to work with the Latigo team to deliver these life-changing non-opioid alternatives to people who desperately need them.”
